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Introduction
The Centers for Disease Control and Prevention (CDC) 
and the U.S. Preventive Services Task Force (USPSTF) 
recommend testing populations that are at increased 
risk for tuberculosis (TB) infection. Once TB disease 
has been ruled out, those who would benefit from 
treatment of latent TB infection (LTBI) should be 
offered this option regardless of their age. Treatment 
adherence and completion are important for those 
who initiate treatment.
Health care providers should consider several criteria 
when classifying positive TST reactions.
Table 1: Criteria for Classifying Positive TST 
Reactions
Positive IGRA result or a TST reaction of 5 or more 
millimeters of induration is considered positive in
 » HIV-infected persons 
 » Recent contacts of a TB case 
 » Persons with fibrotic changes on chest radiograph 
consistent with old TB 
» Organ transplant recipients 
» Persons who are munosuppressed for other reasons (e.g., 
taking the equivalent of >15 mg/day of prednisone for 1
 month or longer, taking TNF-α antagonists) 
Positive IGRA result or a TST reaction of 10 or more 
millimeters of induration is considered positive in
 » Recent immigrants (< 5 years) from high-prevalence 
countries 
 » Injection drug users 
 » Residents and employees of high-risk congregate settings 
(e.g., correctional facilities, nursing homes, homeless 
shelters, hospitals, and other health care facilities) 
 » Mycobacteriology laboratory personnel 
 » Children under 4 years of age, or children and adolescents 
exposed to adults in high-risk categories 
Positive IGRA result or a TST Reaction of 15 or more 
millimeters of induration is considered positive in 
» Persons with no known risk factors for TB*
* Although skin testing programs should be conducted only among high-risk groups, 
certain individuals may require TST for employment or school attendance. An approach 
independent of risk assessment is not recommended by CDC or the American Thoracic 
Society.
Persons at Risk for Developing TB 
Disease
Generally, persons at high risk for developing TB 
disease fall into two categories: those who have an 
increased likelihood of exposure to persons with 
TB disease, and those with clinical conditions that 
increase the risk of progression from LTBI to TB 
disease.
Persons at risk for exposure to persons with TB 
disease include:
 • Close contacts of a person with infectious TB
disease1
 • Persons who have immigrated from areas of the
world with high rates of TB2
 • Residents and employees of high-risk
congregate settings (e.g., correctional facilities,
homeless shelters, health care facilities)2,3
Persons more likely to progress from LTBI to TB 
disease include:
 • Recent converters (those with an increase of
10 mm or more in size of TST reaction within a
2-year period)
 • HIV-infected persons
 • Young children who have a positive TST result4
 • Those with a history of prior, untreated TB or
fibrotic lesions on chest radiograph
 • Injection drug users
 • Those receiving TNF-α antagonists for treatment
of rheumatoid arthritis or Crohn’s disease
Clinical conditions that increase the risk of 
progression from LTBI to TB disease:
 • HIV infection
 • Low body weight (>10% below ideal)
 • Silicosis
 • Diabetes mellitus
 • Chronic renal failure or being on hemodialysis
 • Gastrectomy
 • Jejunoileal bypass
 • Solid organ transplant
 • Head and neck cancer
Special Considerations
Questions often arise about the interpretation 
of TST results in persons with a history of Bacille 
Calmette-Gurin (BCG) vaccine, HIV infection, and 
recent contacts to an infectious TB case.
BCG vaccine is currently used in many parts of 
the world to protect infants and children from 
severe TB disease, especially TB meningitis. 
It does not confer lifelong immunity, and its 
significance in persons receiving the TST causes 
confusion in the medical and lay community.
 • History of BCG vaccine is NOT a
contraindication for tuberculin skin testing
 • TST reactivity caused by BCG vaccine generally
wanes with time
 • If more than 5 years have elapsed since
administration of BCG vaccine, a positive TST
reaction is most likely a result of
M. tuberculosis infection
Persons who are HIV infected have a much 
greater risk for progression to TB disease if they 
have LTBI.
 • Individuals with HIV infection may be unable
to mount an immune response to the TST and
may have false-negative TST results
 • Usefulness of anergy testing in TST-negative
persons who are HIV infected has not been
demonstrated
Persons with a positive TST result who are 
contacts of an individual with infectious TB 
should be treated regardless of age.
 • Some TST-negative persons should also be
considered for treatment (i.e., young children,
immunosuppressed)
 • Repeat TST in 8-10 weeks if initial test result
is negative. A delayed-type hypersensitivity
response to tuberculin is detected 2–8 weeks
after infection
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